Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is currently facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP. The lawsuit alleges that Vistagen made misleading statements regarding its Phase 3 PALISADE-3 trial for fasedienol, a treatment for social anxiety disorder. This pivotal trial subsequently failed to meet its primary endpoint, leading to a dramatic market reaction. Following the announcement, the company's stock price plummeted by over 80%. Investors who incurred losses between April 1, 2024, and December 16, 2025, have until March 16, 2026, to apply for lead plaintiff status in the ongoing legal proceedings.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis